A phase 2 trial reports strong early outcomes for an intensified targeted-drug approach in early-stage classical Hodgkin lymphoma. A regimen pairing two targeted agents with a reduced chemotherapy backbone delivered complete responses in 92% of patients and disease control at an estimated 97% at two years. The headline development is de-escalation: the study suggests a path to maintain efficacy while potentially lowering toxicity exposure compared with more standard multi-agent chemotherapy schedules. For biotech audiences, the immediate relevance is how the regimen’s risk/benefit could influence future trial designs and guideline discussions on treatment sequencing and intensity.